Other · developed by Immatics Biotechnologies GmbH
IMA 401 is an agent given by intravenous infusion at escalating dose levels and at a recommended dose for extension in a trial of patients with refractory or recurrent solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05359445 | Phase 1 | Refractory Cancer | Active not recruiting | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerRecurrent CancerRefractory CancerSolid Tumor, Adult
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →